Stay updated on Selpercatinib in RET+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Selpercatinib in RET+ NSCLC Clinical Trial page.

Latest updates to the Selpercatinib in RET+ NSCLC Clinical Trial page
- Check7 days agoChange DetectedLocation name updated from Napoli, Campania, Italy, 80131 to Naples, Campania, Italy, 80131; page revision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe page now shows Revision: v3.4.3, replacing Revision: v3.4.2.SummaryDifference0.0%

- Check28 days agoChange DetectedIn Turkey, the study site list changed by removing Sarıyer and adding Yellowplace, both with postal code 34457.SummaryDifference0.0%

- Check42 days agoChange DetectedMinor site revision updated from v3.4.1 to v3.4.2; no study content, eligibility criteria, or user-facing actions were changed.SummaryDifference0.0%

- Check50 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1.SummaryDifference0.0%

- Check64 days agoChange DetectedUI and metadata updates include the glossary toggle options (Show glossary, Hide glossary) and a new revision tag (Revision: v3.4.0). The page also updates timestamp-related labels (Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data) and removes older labels (Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, Revision: v3.3.4).SummaryDifference0.1%

Stay in the know with updates to Selpercatinib in RET+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selpercatinib in RET+ NSCLC Clinical Trial page.